Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
The first of several podcasts we'll be adding here from our ASCO 2012 Lung Cancer Highlights program, co-sponsored with LUNGevity Foundation, is with Dr. Mark Socinski, Professor at the University of Pittsburgh, who discussed the updated results of continuation maintenance therapy with Alimta (pemetrexed) on the PARAMOUNT trial. Here is his summary of the presentation that now includes data on the overall survival in that study, which demonstrated a significant benefit for the recipients of continuation maintenance Alimta.
Dr. Socinski ASCO LC Highlights PARAMOUNT Trial Audio Podcast
Dr. Socinski ASCO LC Highlights 2012 PARAMOUNT Trial Transcript
Dr. Socinski ASCO LC Highlights 2012 PARAMOUNT Trial Figs
We'll turn out the podcasts from this program in rapid succession. Look for the next one, with Dr. Socinski reviewing an important trial on poor performance status patients with advanced NSCLC, very soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…